Eton Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ETON | BCRX | IRWD | AMLX | 42C.SI | 002038.SZ | |
|---|---|---|---|---|---|---|
| Market cap | 1.45B | 2.11B | 622.95M | 3.69B | 515.12M | 5.37B |
| P/E (TTM) | 126.8 | — | 4.9 | — | — | — |
| Forward P/E | 19.9 | 10.0 | 2.5 | -27.0 | 247.4 | — |
| Price/book | 30.8 | -14.7 | -3.9 | 13.7 | 33.6 | 1.1 |
| Dividend yield | — | — | — | — | — | 0.19% |
| 1-year change | +164.68% | +17.21% | +69.90% | +135.96% | +259.26% | −31.88% |
| Today | −0.45% | −3.85% | +7.71% | +0.68% | −3.09% | +1.55% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All ETON news ›Eton Pharmaceuticals (ETON) Expected to Announce Quarterly Earnings on Thursday
Posted by Kim Johansen on Nov 4th, 2026 Read Our Latest Research Report on ETON Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions…
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
“The planned clinical trial is also warranted because studies of spasms patients with structural brain abnormalities indicate that IGF-1 levels are reduced in their brains. Consequently, we hope that mecasermin/IGF-1 will serve as a…
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ('Eton” or the 'Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today…
Eton Pharmaceuticals Has Stronger Earnings And A Little Valuation Cushion
Eton Pharmaceuticals at the current valuation already reflects strong 2027 growth and a premium multiple. Learn why ETON stock is a hold. - Eton Pharmaceuticals at the current valuation already reflects strong 2027 growth and a premium…
Contrasting Eton Pharmaceuticals (NASDAQ:ETON) and Biofrontera (NASDAQ:BFRI)
Posted by Tristan Rich on Oct 24th, 2026 Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) and Biofrontera (NASDAQ:BFRI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
Eton Pharmaceuticals licenses cheek-film seizure drug for U.S. market
Crain's Chicago Business Eton Pharmaceuticals licenses cheek-film seizure drug for U.S. marketâ Introducing 40 young leaders already putting their imprint on the businesses, institutions and communities shaping our future.
Eton Pharmaceuticals licenses LIBERVANT for $10M upfront
INVE Technologies Announces the Commencement of a $20 Million Modified Dutch Auction Tender Offer for its Common Stock TNL Mediagene Announces $6.25 Million Strategic Investment from Vector Advisory Partners and Anticipated Change of…
Eton Pharmaceuticals (NASDAQ:ETON) Stock Keeps “Buy” Rating at HC Wainwright
Posted by Danessa Lincoln on Oct 14th, 2026 Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports.…
More from 1 other outlet
Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
TradingView Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
The license gives Eton a neurology commercialization opportunity, but the anticipated April 2027 launch remains subject to final FDA approval. An application to add ages 6 to 11 is under FDA review, with a March 29, 2027 target action…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com4
- stocktitan.net3
- defenseworld.net2
- chicagobusiness.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.